Zymeworks Inc.

DB:ZA8 Stock Report

Market Cap: €1.7b

Zymeworks Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Ken Galbraith

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage12.46%
CEO tenure4yrs
CEO ownership0.2%
Management average tenure2.5yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ken Galbraith's remuneration changed compared to Zymeworks's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$63m

Jun 30 2025n/an/a

-US$74m

Mar 31 2025n/an/a

-US$114m

Dec 31 2024US$5mUS$655k

-US$123m

Sep 30 2024n/an/a

-US$114m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$3mUS$625k

-US$119m

Sep 30 2023n/an/a

US$205m

Jun 30 2023n/an/a

US$186m

Mar 31 2023n/an/a

US$173m

Dec 31 2022US$7mUS$582k

US$124m

Sep 30 2022n/an/a

-US$224m

Jun 30 2022n/an/a

-US$237m

Mar 31 2022n/an/a

-US$240m

Dec 31 2021n/an/a

-US$212m

Sep 30 2021n/an/a

-US$211m

Jun 30 2021n/an/a

-US$223m

Mar 31 2021n/an/a

-US$194m

Dec 31 2020n/an/a

-US$181m

Sep 30 2020n/an/a

-US$215m

Jun 30 2020n/an/a

-US$173m

Mar 31 2020n/an/a

-US$163m

Dec 31 2019US$167kn/a

-US$145m

Compensation vs Market: Ken's total compensation ($USD5.25M) is above average for companies of similar size in the German market ($USD1.71M).

Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.

CEO

Ken Galbraith (63 yo)

4yrs
Tenure
US$5,253,616
Compensation

Mr. Kenneth H. Galbraith, also known as Ken, C. A., is Director of AudienceView Ticketing Corporation. He serves as Chairman of Zomp. He is Director of NeurAxon Inc. He is CEO & Chairman of the Board of Zy...

Leadership Team

NamePositionTenureCompensationOwnership
Kenneth Galbraith
Chairman of the Board4yrsUS$5.25m0.18%
€ 3.0m
Leone Patterson
Executive VP and Chief Business & Financial Officer1.3yrsUS$2.91mno data
Scott Platshon
Acting Chief Investment Officerless than a yearno datano data
Paul Moore
Chief Scientific Officer3.5yrsUS$1.99m0.031%
€ 530.2k
Mark Hollywood
Executive VP and Head of Technical & Manufacturing Operationsno datano datano data
Shrinal Inamdar
Director of Investor Relationsno datano datano data
Daniel Dex
Senior VPno datano datano data
Diana Papove
Senior Manager of Corporate Communicationsno datano datano data
Lindsey Foulkes
Vice President of Corporate Developmentno datano datano data
Laura O'Connor
Vice President of Human Resources & DEI3yrsno datano data
Jeffrey Smith
Executive VP & Chief Medical Officerno datano datano data
John Fann
Senior Vice President of Process Sciences2yrsno datano data
2.5yrs
Average Tenure
60.5yo
Average Age

Experienced Management: ZA8's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kenneth Galbraith
Chairman of the Board4yrsUS$5.25m0.18%
€ 3.0m
Kelvin Neu
Independent Director5.8yrsUS$296.47k0%
€ 0
Robert Landry
Independent Directorless than a yearno datano data
Susan Mahony
Lead Independent Director6.6yrsUS$314.60k0%
€ 0
Oleg Nodelman
Independent Directorless than a yearno datano data
Alessandra Cesano
Independent Director1.9yrsUS$810.23k0%
€ 0
Gregory Ciongoli
Independent Directorless than a yearno data0.66%
€ 11.2m
Carlos Campoy
Independent Director2.6yrsUS$306.47k0%
€ 0
2.3yrs
Average Tenure
60.5yo
Average Age

Experienced Board: ZA8's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/04 23:31
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zymeworks Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Mayank MamtaniB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity